Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives

University of Ottawa

$100,000.00

Development and Optimization of Novel Chimeric Antigen Receptor NK-cell Therapeutics for B-Cell Malignancy

FY 2019-20 · 2020-03-31

Summary
To assess the functionality of novel NRC-developed chimeric antigen receptors (CARs) targeting leukemia in primary NK cells and assessment of CAR-NK potential for therapeutic development, expanded primary NK cells will be transduced, and their anti-tumor response will be evaluated in vitro and in vivo.
Program
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Location
Ottawa, Ontario, Canada
Recipient Type
Academia
Business Number
119278877
Type
Grant
Source
Proactive Disclosure - Grants and Contributions

As published

Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 184 days. The total amended value is 50,000 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 184 jours. La valeur totale des modifications est de 50 000 dollars.
Agreement End Date
2021-03-31
Agreement Number
947410
Agreement Start Date
2020-03-31
Agreement Title
Development and Optimization of Novel Chimeric Antigen Receptor NK-cell Therapeutics for B-Cell Malignancy
Agreement Title (French)
Mise au point et optimisation de nouvelles techniques thérapeutiques ciblées sur la prolifération maligne des lymphocytes B et utilisant des cellules tueuses naturelles (NK) dotées d’un récepteur antigénique chimérique
Agreement Type
Grant
Agreement Value
$100,000.00
Amendment Number
0
Description
To assess the functionality of novel NRC-developed chimeric antigen receptors (CARs) targeting leukemia in primary NK cells and assessment of CAR-NK potential for therapeutic development, expanded primary NK cells will be transduced, and their anti-tumor response will be evaluated in vitro and in vivo.
Description (French)
Pour évaluer d’une part la fonctionnalité de nouveaux récepteurs d’antigènes chimériques (CAR) mis au point au CNRC et visant la leucémie dans les cellules tueuses naturelles (NK) et d’autre part le potentiel d’une telle thérapie CAR-NK, des cellules NK primaires seront transduites et leur réponse antitumorale sera évaluée in vitro et in vivo.
Expected Results
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Expected Results (French)
À court terme, les résultats prévus seront des collaborations renforcées entre l'industrie, le milieu universitaire et le gouvernement pour soutenir l'excellence en recherche. À moyen terme, les résultats attendus seront le développement de nouvelles technologies potentiellement perturbatrices avec des collaborateurs. À long terme, trouver des solutions collaboratives aux défis des politiques publiques et créer des systèmes d'innovation plus solides.
Federal Riding
Ottawa–Vanier
Federal Riding (French)
Ottawa–Vanier
Federal Riding Number
35078
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Name (French)
Programme de collaboration en science, en technologie et en innovation - Initiatives de collaboration en R-D
Program Purpose
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
Program Purpose (French)
Collaborer à des programmes multipartites de recherche-développement dans le but de profiter de la synergie entre la recherche transformatrice à haut risque et à haut rendement et le potentiel de découvertes scientifiques et de percées technologiques révolutionnaires dans des secteurs d’intervention prioritaires.
Recipient Business Number
119278877
Recipient City
Ottawa
Recipient Country
CA
Recipient Legal Name
University of Ottawa
Recipient Operating Name
University of Ottawa
Recipient Postal Code
K1N 6N5
Recipient Province or Territory
ON
Recipient Type
S
Reference Number
172-2019-2020-Q4-947410